Engineered T-Cells Market
According to Intent Market Research, the Engineered T-Cells Market is expected to grow from USD 3.5 billion in 2023 at a CAGR of 15.1% to touch USD 9.2 billion by 2030. The Engineered T-Cells Market is dominated by key players such as, Gilead Sciences, Inc. (Kite Pharma), Novartis AG, Celgene Corporation, CRISPR Therapeutics AG, and Allogene Therapeutics, Inc